Sharon X. Wen

Array ( [id] => 11743960 [patent_doc_number] => 20170198033 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-13 [patent_title] => 'SULFONATED SCLEROSTIN, ANTIBODIES, EPITOPES AND METHODS FOR IDENTIFICATION AND USE THEREFOR' [patent_app_type] => utility [patent_app_number] => 15/447496 [patent_app_country] => US [patent_app_date] => 2017-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 10254 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15447496 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11949514 [patent_doc_number] => 20170253666 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-07 [patent_title] => 'Methods for Treating Patients with Hyperlipidemia by Administering a PCSK9 Inhibitor in Combination with an ANGPTL3 Inhibitor' [patent_app_type] => utility [patent_app_number] => 15/446720 [patent_app_country] => US [patent_app_date] => 2017-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 14430 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15446720 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11969833 [patent_doc_number] => 20170273987 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-28 [patent_title] => 'Methods for Treating GI Syndrome and Graft versus Host Disease' [patent_app_type] => utility [patent_app_number] => 15/437165 [patent_app_country] => US [patent_app_date] => 2017-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 26807 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15437165 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12254231 [patent_doc_number] => 09926367 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-03-27 [patent_title] => 'Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof' [patent_app_type] => utility [patent_app_number] => 15/430100 [patent_app_country] => US [patent_app_date] => 2017-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 13411 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15430100 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11649489 [patent_doc_number] => 20170145391 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-25 [patent_title] => 'TRUNCATED VARIANT OF THE MAMMALIAN TARGET FOR RAPAMYCIN (mTOR) PROTEIN' [patent_app_type] => utility [patent_app_number] => 15/423377 [patent_app_country] => US [patent_app_date] => 2017-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 24402 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15423377 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12051252 [patent_doc_number] => 20170327595 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-16 [patent_title] => 'THERAPEUTIC AND DIAGNOSTIC METHODS RELATED TO LYSYL OXIDASE-LIKE 2 (LOXL2)' [patent_app_type] => utility [patent_app_number] => 15/416940 [patent_app_country] => US [patent_app_date] => 2017-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 43 [patent_no_of_words] => 40069 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15416940 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11992480 [patent_doc_number] => 20170296635 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-19 [patent_title] => 'COMPOSITIONS AND METHODS COMPRISING GLYCYL-TRNA SYNTHETASES HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES' [patent_app_type] => utility [patent_app_number] => 15/415328 [patent_app_country] => US [patent_app_date] => 2017-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 22413 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15415328 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15754077 [patent_doc_number] => 10619136 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-04-14 [patent_title] => Reducing immune tolerance induced by PD-L1 [patent_app_type] => utility [patent_app_number] => 15/373012 [patent_app_country] => US [patent_app_date] => 2016-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 13840 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 139 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15373012 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17890764 [patent_doc_number] => 11453717 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-27 [patent_title] => Trispecific antibodies against IL-17A, IL-17F and other pro-inflammatory molecule [patent_app_type] => utility [patent_app_number] => 16/097562 [patent_app_country] => US [patent_app_date] => 2016-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 29 [patent_no_of_words] => 27732 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16097562 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15280079 [patent_doc_number] => 10512689 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-24 [patent_title] => Compositions comprising a combination of nivolumab and ipilimumab [patent_app_type] => utility [patent_app_number] => 15/365717 [patent_app_country] => US [patent_app_date] => 2016-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 34 [patent_no_of_words] => 38239 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15365717 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16198638 [patent_doc_number] => 10723788 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-07-28 [patent_title] => Anti-complement factor C1q Fab fragments and uses thereof [patent_app_type] => utility [patent_app_number] => 15/360549 [patent_app_country] => US [patent_app_date] => 2016-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 24641 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15360549 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11491495 [patent_doc_number] => 20170065681 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-09 [patent_title] => 'USE OF CGRP ANTAGONIST COMPOUNDS FOR TREATMENT OF PSORIASIS' [patent_app_type] => utility [patent_app_number] => 15/355723 [patent_app_country] => US [patent_app_date] => 2016-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 13499 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15355723 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13607021 [patent_doc_number] => 20180355059 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-13 [patent_title] => ANTI-PCSK9 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/768032 [patent_app_country] => US [patent_app_date] => 2016-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18157 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15768032 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16590577 [patent_doc_number] => 10899827 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-26 [patent_title] => Antibodies specific for sulfation sites of sclerostin [patent_app_type] => utility [patent_app_number] => 15/273000 [patent_app_country] => US [patent_app_date] => 2016-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 17406 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15273000 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17236697 [patent_doc_number] => 11180569 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-23 [patent_title] => Methods of treating autoimmune disorders using a combination of anti-CD20 and anti-blys antibodies [patent_app_type] => utility [patent_app_number] => 15/762195 [patent_app_country] => US [patent_app_date] => 2016-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5628 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15762195 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11469721 [patent_doc_number] => 20170056504 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-02 [patent_title] => 'METHOD OF EXTENDING HALF-LIFE OF CRYSTALINE ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 15/254316 [patent_app_country] => US [patent_app_date] => 2016-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 11555 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15254316 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17858558 [patent_doc_number] => 11439696 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-13 [patent_title] => Modulation of proprotein convertase subtilisin/kexin 9 expression (PCSK9) with HSP 27 and/or HSP25 [patent_app_type] => utility [patent_app_number] => 15/756282 [patent_app_country] => US [patent_app_date] => 2016-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 65 [patent_no_of_words] => 15399 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15756282 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11455981 [patent_doc_number] => 20170049886 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-23 [patent_title] => 'METHODS FOR REDUCING OR ELIMINATING THE NEED FOR LIPOPROTEIN APHERESIS IN PATIENTS WITH HYPERLIPIDEMIA BY ADMINISTERING A PCSK9 INHIBITOR' [patent_app_type] => utility [patent_app_number] => 15/238890 [patent_app_country] => US [patent_app_date] => 2016-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 23544 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15238890 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11542669 [patent_doc_number] => 20170096494 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-06 [patent_title] => 'POLYPEPTIDE STRUCTURAL MOTIFS ASSOCIATED WITH CELL SIGNALING ACTIVITY' [patent_app_type] => utility [patent_app_number] => 15/239399 [patent_app_country] => US [patent_app_date] => 2016-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 28186 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15239399 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13357783 [patent_doc_number] => 20180230431 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-16 [patent_title] => Combination Therapy [patent_app_type] => utility [patent_app_number] => 15/749984 [patent_app_country] => US [patent_app_date] => 2016-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29284 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15749984 [rel_patent_id] =>[rel_patent_doc_number] =>)